SEQUENTIAL HIGH-DOSE METHOTREXATE AND FLUOROURACIL COMBINED WITH DOXORUBICIN - A STEP AHEAD IN THE TREATMENT OF ADVANCED GASTRIC-CANCER - A TRIAL OF THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER GASTROINTESTINAL-TRACT COOPERATIVE GROUP

被引：340

作者：

WILS, JA

KLEIN, HO

WAGENER, DJT

BLEIBERG, H

REIS, H

KORSTEN, F

CONROY, T

FICKERS, M

LEYVRAZ, S

BUYSE, M

DUEZ, N

机构：

[1] DE WEVER HOSP,HEERLEN,NETHERLANDS

[2] UNIV COLOGNE,MED KLIN,W-5000 COLOGNE 41,GERMANY

[3] INST JULES BORDET,B-1000 BRUSSELS,BELGIUM

[4] CTR ALEXIS VAUTRIN,F-54500 VANDOEUVRE NANCY,FRANCE

[5] CHU VAUDOIS,CH-1011 LAUSANNE,SWITZERLAND

[6] RADBOUD HOSP,NIJMEGEN,NETHERLANDS

[7] MARIA HILF KRANKENHAUS,MONCHEN GLADBACH,GERMANY

[8] EUROPEAN ORG RES TREATMENT CANC,CTR DATA,BRUSSELS,BELGIUM

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1991年 / 9卷 / 05期

关键词：

D O I：

10.1200/JCO.1991.9.5.827

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a prospective phase III multicenter trial, 213 patients with advanced measurable or nonmeasurable gastric cancer were randomized to receive methotrexate (MIX), fluorouracil (5-FU), and Adriamycin (doxorubicin; Farmitalia Carlo Erba, Milan, Italy) (FAMTX) or 5-FU, Adriamycin, and mitomycin (FAM). The results show a significantly superior response rate (41% v 9% [P < .0001]), and survival (median, 42 weeks v 29 weeks [P = .004]) for FAMTX. There was a cumulative thrombocytopenia in FAM and not in FAMTX. The FAMTX protocol should be the reference treatment in future clinical trials that seek to improve the therapeutic outcome in advanced gastric cancer. © 1991 by American Society of Clinical Oncology.

引用

页码：827 / 831

页数：5

共 11 条

[1]

BERTINO JR, 1977, CANCER RES, V37, P327

[2]

BROWMAN GP, 1984, CANCER TREAT REP, V68, P465

[3] ENHANCED 5-FLUOROURACIL NUCLEOTIDE FORMATION AFTER METHOTREXATE ADMINISTRATION - EXPLANATION FOR DRUG SYNERGISM [J].

CADMAN, E ;

HEIMER, R ;

DAVIS, L .

SCIENCE, 1979, 205 (4411) :1135-1137

[4]

KELSEN D, 1990, P AN M AM SOC CLIN, V9, P121

[5]

KLEIN H O, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P84

[6]

KLEIN HO, 1989, MED ONCOL TUMOR PHAR, V6, P171

[7]

KLEIN HO, 1982, DEUT MED WOCHENSCHR, V45, P1708

[8] PHASE-II STUDY WITH THE COMBINATION ETOPOSIDE, DOXORUBICIN, AND CISPLATIN IN ADVANCED MEASURABLE GASTRIC-CANCER [J].

PREUSSER, P ;

WILKE, H ;

ACHTERRATH, W ;

FINK, U ;

LENAZ, L ;

HEINICKE, A ;

MEYER, J ;

MEYER, HJ ;

BUENTE, H .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1310-1317

[9] AN EORTC GASTROINTESTINAL GROUP EVALUATION OF THE COMBINATION OF SEQUENTIAL METHOTREXATE AND 5-FLUOROURACIL, COMBINED WITH ADRIAMYCIN IN ADVANCED MEASURABLE GASTRIC-CANCER [J].

WILS, J ;

BLEIBERG, H ;

DALESIO, O ;

BLIJHAM, G ;

MULDER, N ;

PLANTING, A ;

SPLINTER, T ;

DUEZ, N .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (12) :1799-1803

[10] CURRENT STATUS OF CHEMOTHERAPY FOR GASTRIC-CANCER [J].

WILS, J ;

BLEIBERG, H .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (01) :3-8

← 1 2 →